Trials / Completed
CompletedNCT03566134
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
A Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Therapeutic Exploratory Clinical Study to evaluate the efficacy and safety of DA-8010 in Patients with Overactive Bladder and to determine the optimal dose of DA-8010
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-8010 Placebo | Participants receive placebo to match DA-8010 orally once a day. |
| DRUG | DA-8010 2.5mg | Participants receive DA-8010 2.5mg orally once a day. |
| DRUG | DA-8010 5mg | Participants receive DA-8010 5mg orally once a day. |
| DRUG | Solifenacin 5mg | Participants receive solifenacin 5 mg orally once a day. |
| DRUG | Solifenacin succinate placebo | Participants receive placebo to match solifenacin 5 mg orally once a day. |
Timeline
- Start date
- 2018-07-10
- Primary completion
- 2019-12-27
- Completion
- 2019-12-27
- First posted
- 2018-06-21
- Last updated
- 2020-02-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03566134. Inclusion in this directory is not an endorsement.